Replies to post #389515 on Elite Pharmaceuticals Inc (ELTP)

[sharkey1]

THX

[NASDAQ2020]

HammerTime !!

More to come.
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million launched
X 4. In house marketing and distribution: Kirkov
--5. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million
X 6. DEA increases manufacturing quotas of Adderall & Vyvance
X 7. Double digit quarterly revenues in millions.
—8. Full ownership of Adderall IR $ 335 Million LAUNCHED
—9. Full ownership of Adderall XR $ 1.56 Billion LAUNCHED
—10. Generic Concerta- $1.2 BILLION
—11. Generic Vyvanse- $5.3 BILLION
—12. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge
—13. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
—14. Patented Unique ADF (w/o naltrexone)-- NDA
—15. Mikah ANDA (s)
—16. Undisclosed (s)
—17. Antimetabolite ANDA- Methotrexate -$600 Million
—18. Undisclosed Antimetabolite ANDA- $42 Million
X 19. Prasco/Burel Adderall agreement January 1st 2024
—20. Triple digit yearly revenues in millions.
—21. European distribution Dexcel partnership approval by Israeli Health
—22. Purchase or rent additional manufacturing space for new ANDAs
—23. Uplist to the NASDAQ Exchange
—24. THE Buy Out !